Noticias y Actividades de Exelixis

Exelixis es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Exelixis es una empresa que cotiza bajo el símbolo de cotización EXEL (US).

Ver el organigrama con sus 21 ejecutivos principales

Biografías más buscadas en Exelixis

• Michael Morrissey, Director, Chief Executive Officer and President
• Stelios Papadopoulos, Chairman of the Board
• Bob Oliver, Director

Crear su alerta
para seguir los movimientos de los ejecutivos en Exelixis.

Exelixis tiene 2.339 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Biogen (Estados Unidos).

Popular M&A news in Biotecnología

• Jade Biosciences and Aerovate Therapeutics have announced they will merge  (publicado el 30 de abril de 2025)..
• Deepull acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 29 de abril de 2025).
• Biolinq acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 23 de abril de 2025).

Otros contactos sugeridos en el sector Biotecnología

• Kristina Burow - Director en Scholar Rock
• Herriot Tabuteau - Chief Executive Officer and Director en Axsome Therapeutics
• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Exelixis

• Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 | Exelixis, Inc.
• Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer | Exelixis, Inc.
• Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies | Exelixis, Inc.
• Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference | Exelixis, Inc.
• Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer | Exelixis, Inc.
• Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies | Exelixis, Inc.
• Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June | Exelixis, Inc.
• Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 | Exelixis, Inc.
• Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 | Exelixis, Inc.
• Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update | Exelixis, Inc.
• View more press releases Close

Redes sociales sobre Exelixis

• Exelixis en Wikipedia, Google News y Yahoo Finance
• Exelixis en LinkedIn, Twitter y YouTube